Auro Vaccines

Auro Vaccines, a wholly-owned subsidiary of Aurobindo Pharma USA, is a clinical-stage biotech focused on a fundamental new approach to vaccine design. Its proprietary PBS Vax™ platform allows precise 'tuning' of immune responses to overcome the shortcomings of current DNA and classic prophylactic vaccines. The company has established a pipeline targeting high-unmet-need areas like HPV-associated cervical dysplasia, SARS-CoV-2, Chikungunya, and RSV, and maintains significant partnerships with entities like Emergent BioSolutions and CEPI for filovirus and other outbreak pathogen vaccines.

Prime/Boost System of Vaccines (PBS Vax™) platform that enables quantitative and qualitative 'tuning' of immune responses (humoral or cellular) to specific pathogen targets for both preventive and therapeutic applications.

Total raised: $17.4M

Auro Vaccines faces competition from large pharmaceutical companies (GSK, Pfizer, Moderna, J&J) with substantial resources and approved products, particularly in RSV and pandemic response. Its differentiation hinges on the claimed precision and tunability of its PBS Vax™ platform to generate optimized immune responses, a feature it must demonstrate clinically to gain a competitive edge.